Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/22461
Title: Factors Affecting Postoperative Morbidity and Mortality in Patients Who Received Neoadjuvant Therapy for Lung Cancer
Authors: Karapinar, K
Aydoğmuş, Ümit
Cansever, L
Kocaturk, C
Saydam, O
Bedirhan, MA
Keywords: Lung Cancer; Neoadjuvant Treatment; Mediastinal Lymph Node Invasion;
Morbidity; Mortality
Publisher: DERMAN MEDICAL PUBL
Abstract: Aim: The aim of this study was to investigate the factors that affect mortality and morbidity (MM) in patients with non-small lung cell cancer (NSCLC) who received Neoadjuvant Therapy (NT) for mediastinal lymph node invasion (M LN I) before the surgery. Material and Method: Twentyfour NSCLC patients who received NT for M LN I before surgery were selected as the study group. Thirty patients who were operated without receving NT were constituted the control group. Major complications (MAC) including pneumonia, empyema, chylothorax Minor complications (MIC) including prolonged air leak, arrhythmia, anemia, hoarseness, and wound site infection were determined. Patients were evaluated retrospectively. Results: It was found that life threatening postoperative MAC increased significantly after NT (p=0.04), and MIC or factors causing them did'nt affect the morbidity, NT had no effect on survival. Discussion: Surgery for NSCLC after NT for MLNI increases major morbidities. Careful preoperative assessment, experienced surgical team and appropriate intensive care conditions will reduce MM. Therefore the risk of MM should minimized with wider and prospective studies.
URI: https://hdl.handle.net/11499/22461
https://doi.org/10.4328/JCAM.2935
ISSN: 1309-0720
Appears in Collections:Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

WEB OF SCIENCETM
Citations

2
checked on Jul 17, 2024

Page view(s)

46
checked on May 27, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.